Guang Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Guang Yang has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Guohui Liu
Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun130033, China
1 shared publicationHaikuo Zheng
Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun130033, China
1 shared publicationWei Nie
Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun130033, China
1 shared publicationZhe An
Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun130033, China
1 shared publication
Latest Publications
- Open Access
- 23 October 2017
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 12 (1) , 337-344
Biomarkers in patients with myocardial fibrosis
Myocardial fibrosis is observed in many cardiovascular diseases including hypertension, heart failure and cardiomyopathy. Myocardial fibrosis has been proved to be reversible and treatable only under timely intervention, which makes early detection and assessment of fibrosis crucial. Aside from tissue biopsy as the gold standard for the diagnosis of myocardial fibrosis, circulating biomarkers have been adopted as noninvasive assessment of this lesion. Dysregulated collagen deposition is thought to be the major cause of myocardial fibrosis. Collagens, procollagens, TGF-β, TIMP, galectin-3, and microRNAs are thought to be indicators of myocardial fibrosis. In this review, we summarize the molecules that are frequently used as biomarkers in diagnosis of cardiac fibrosis. Mechanisms of fibrosis that they take part in are also introduced.
- 23 October 2017
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 12 (1) , 337-344
Open AccessBiomarkers in patients with myocardial fibrosis
Myocardial fibrosis is observed in many cardiovascular diseases including hypertension, heart failure and cardiomyopathy. Myocardial fibrosis has been proved to be reversible and treatable only under timely intervention, which makes early detection and assessment of fibrosis crucial. Aside from tissue biopsy as the gold standard for the diagnosis of myocardial fibrosis, circulating biomarkers have been adopted as noninvasive assessment of this lesion. Dysregulated collagen deposition is thought to be the major cause of myocardial fibrosis. Collagens, procollagens, TGF-β, TIMP, galectin-3, and microRNAs are thought to be indicators of myocardial fibrosis. In this review, we summarize the molecules that are frequently used as biomarkers in diagnosis of cardiac fibrosis. Mechanisms of fibrosis that they take part in are also introduced.